
AstraZeneca is expected to generate almost $600 million from just two drug sales: Zoming, a migraine therapy, and Seloken, a …

AstraZeneca announced that it had sold the European rights to its drug, Seloken (metoprolol), to Italian pharmaceutical company Recordati. The …

